Payment overview · 2025
General Payments
$2,693.79
43 reported records · 11 companies
Healthcare provider profile · identity verified
Millard James Collier, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITHIA SPRINGS, GA · NPI 1306860044
Verified facts
What the public records show
CMS Open Payments records show Millard James Collier, M.D. received $2,693.79 in general payments during 2025 across 43 reported records.
LifeNet Health accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbyclor, Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LifeNet Health | Unresolved — no canonical attribution shown | $1,047.62 | 38.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $449.33 | 16.7% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $434.43 | 16.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $406.19 | 15.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.99 | 6.3% | 10 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.53 | 1.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.01 | 1.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $39.61 | 1.5% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.02 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.46 | 0.7% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.60 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,586.06 | 39 |
| Travel and Lodging | $845.23 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $262.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $1,047.62 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $434.43 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $262.50 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $243.24 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $143.69 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.72 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.72 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.83 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBYCLOR edarbyclor |
2025 | Edarbyclor | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 205 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
205 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 399 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 114 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 310 | 35 |
| Ozempic | Semaglutide | 205 | 27 |
| Allopurinol | Allopurinol | 184 | 60 |
| Famotidine | Famotidine | 153 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 45 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 138 | 39 |
| Carvedilol | Carvedilol | 125 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 34 |
| Tramadol Hcl | Tramadol Hcl | 124 | 20 |
| Metformin Hcl | Metformin Hcl | 121 | 36 |
| Potassium Chloride | Potassium Chloride | 119 | 39 |
| Gabapentin | Gabapentin | 116 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 113 | 42 |
| Jardiance | Empagliflozin | 107 | 25 |
| Omeprazole | Omeprazole | 106 | 33 |
| Lorazepam | Lorazepam | 98 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | suppressed |
| Meloxicam | Meloxicam | 84 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 21 |
| Farxiga | Dapagliflozin Propanediol | 76 | 18 |
| Simvastatin | Simvastatin | 74 | 22 |
| Lisinopril | Lisinopril | 72 | 22 |
| Azithromycin | Azithromycin | 71 | 47 |
| Carisoprodol | Carisoprodol | 68 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 15 |
| Losartan Potassium | Losartan Potassium | 63 | 19 |
| Celecoxib | Celecoxib | 59 | 21 |
| Metformin Hcl Er | Metformin Hcl | 59 | 20 |
| Pregabalin | Pregabalin | 59 | 18 |
| Montelukast Sodium | Montelukast Sodium | 57 | 17 |
| Trazodone Hcl | Trazodone Hcl | 57 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 11 |
| Nifedipine Er | Nifedipine | 47 | 17 |
| Valacyclovir | Valacyclovir Hcl | 45 | 14 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Verapamil Er | Verapamil Hcl | 44 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 42 | 14 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 24 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 37 | suppressed |
| Finasteride | Finasteride | 37 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 20 |
| Eliquis | Apixaban | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | 12 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Furosemide | Furosemide | 22 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | 12 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,693.79 · 43 records | LifeNet Health | AIRSUPRA, AZMIRO, BREZTRI, CRYSVITA, Cologuard Collection Kit, EDARBI, EDARBYCLOR, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, Ozempic, Rybelsus, TOLMETIN SODIUM, The Cologuard Plus Collection Kit, TheraGenesis Wound Matrix, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbyclor play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error